Search results

1. ESMO 2023 – red flags for PSMAfore

   ESMO 2023 – red flags for PSMAfore Full …

   
    

   Madeleine Armstrong
    
   - 10/30/2023 - 16:21

2. ESMO 2023 – Biontech’s Neon buy fails to shine

   ESMO 2023 – Biontech’s Neon buy fails to shine …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 15:38

3. ESMO 2023 – regulators come under fire for Retevmo trial requirements

   ESMO 2023 – regulators come under fire for Retevmo trial …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 15:37

4. ESMO 2023 – more hope for a new Car-T target

   ESMO 2023 – more hope for a new Car-T target … – 1 PR (KRASm tumour) in 9 patients reported at ESMO 2023 PF-07062119 T-cell engager Pfizer …

   
    

   Jacob Plieth
    
   - 10/23/2023 - 15:38

5. ESMO 2023 – the colorectal KRAS pipeline swells again

   ESMO 2023 – the colorectal KRAS pipeline swells again … TRAEs 36% 30% 13% 16% 41% Source: ESMO 2023, AACR 2023 & ESMO 2022. …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 14:44

6. ESMO 2023 – Padcev hits its home run

   ESMO 2023 – Padcev hits its home run …

   
    

   Jacob Plieth
    
   - 10/27/2023 - 17:39

7. ESMO 2023 – Daiichi shows why Merck paid $1.5bn for CDH6

   ESMO 2023 – Daiichi shows why Merck paid $1.5bn for CDH6 …

   
    

   Jacob Plieth
    
   - 10/23/2023 - 15:15

8. ESMO 2023 – low-dose volrustomig hints at a therapeutic window

   ESMO 2023 – low-dose volrustomig hints at a therapeutic …

   
    

   Jacob Plieth
    
   - 10/22/2023 - 18:42

9. ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition

   ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition …

   
    

   Madeleine Armstrong
    
   - 01/17/2024 - 16:18

10. ESMO 2023 – Merck makes its KRAS entrance

    ESMO 2023 – Merck makes its KRAS entrance … in TPS ≥50%; TPS=tumour proportion score; *reported at ESMO 2023; **reported at ESMO-IO Dec 2022. …

    
     

    Madeleine Armstrong
     
    - 10/22/2023 - 14:04